Company / Operating Cash Flow
Bristol Myers Squibb Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$14.2B
FY2025
5-year range
$8.2B / $16.2B
FY2021-FY2025
Trend
-6.8%
vs FY2024
Sector context
#5 of 216
Health Care
What the data says
Among 216 Health Care companies, Bristol Myers Squibb is in the top 2% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from $3.1B in FY2018 to $16.2B in FY2023.
Based on SEC 10-K filings.
$14.2B in FY2025 with a 5-year CAGR of +0.1%. Top quartile in the Health Care sector.
Declined from $16.2B to $14.2B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +0.2%
- 5-Year CAGR
- +0.1%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 216This company $14.2B Sector average $658.7M
▼
+2049.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +0.1%, indicating consistent growth.
- In FY2025, operating cash flow decreased 6.8% year-over-year.
- Ranks #5 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.2B | -6.8% |
| FY2024 | $15.2B | -6.3% |
| FY2023 | $16.2B | +15.3% |
| FY2022 | $14.1B | +71.2% |
| FY2021 | $8.2B | -41.6% |
| FY2020 | $14.1B | +166.4% |
| FY2019 | $5.3B | +72.5% |
| FY2018 | $3.1B | -42.0% |
| FY2017 | $5.3B | +67.6% |
| FY2016 | $3.1B | -11.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026